SKU: 88867085907

Duhaney Clinical Trials Investment Dashboard

Sale price$5400.00 Regular price$6000.00
Save 10%

Shipping Estimate
USA
  • USA
  • CAN

Ships within 48 hours · Estimated delivery Jul 12 - Jul 17

Promo Codes Available:

For Your Every Summer RSVP, with Code: SUMMER15

Description

Duhaney Clinical Trials Investment DashboardDuhaney Real Estate Deal Command Center Full Ecosystem Duhaney Clinical Trials Investment Dashboard Your Insider Guide to Drug Success & ROI Starting Price: $1500. 00 USD The Truth About Clinical Trials Nobody Tells You If youve ever tried to predict which drug will win FDA approval, or which trial will attract the next big investment, you already know the truth **the data is scattered, outdated, and full of noise**. Most clinical reports tell you

Duhaney Real Estate Deal Command Center – Full Ecosystem

Duhaney Clinical Trials Investment Dashboard – Your Insider Guide to Drug Success & ROI

Starting Price: $1500.00 USD

The Truth About Clinical Trials Nobody Tells You

If you’ve ever tried to predict which drug will win FDA approval, or which trial will attract the next big investment, you already know the truth — **the data is scattered, outdated, and full of noise**.

Most clinical reports tell you **what happened**, but they never tell you **what it really means for your investment, your startup, or your next move**.

---

Let’s Deframe That Entire Process

Why guess when you could have a **real-time dashboard** that connects the dots between:

  • ✅ Which sponsors dominate in each therapeutic area
  • ✅ The **real cost per patient** by condition and phase
  • ✅ The historical **ROI for every major trial category**
  • ✅ Which drugs have **the highest probability of approval**
  • ✅ And exactly which conditions are pulling the most investment dollars right now

---

Now Let’s Reframe — What You’re Actually Getting

The **Duhaney Clinical Trials Investment Dashboard** isn’t a static report — it’s your **decision engine**. Every time you need to answer questions like:

  • 💰 Which drug is about to make investors rich?
  • 📊 Which sponsor should my startup partner with?
  • ⚕️ Which condition is about to have a blockbuster approval?
  • 📈 What’s the **per-patient cost vs revenue potential** for each drug?
  • 🔍 Which trials are actually worth tracking — and which are just noise?

…you load the dashboard and the answers are right there.

---

What’s Inside Your Personalized Dashboard

✅ Pre-loaded with the **top 50 therapeutic areas** (Sickle Cell, Oncology, Rare Diseases, and more) ✅ Full **financial modeling** — cost per patient, projected revenue per patient, and calculated ROI ✅ FDA study phases & statuses — see which trials are closest to approval ✅ Sponsor and CRO performance tracking — know who delivers and who burns money ✅ Real-time NCT Number cross-referencing — no more disconnected data

---

Why This Dashboard is Different

✅ **Built directly from FDA clinicaltrials.gov data** — no second-hand garbage ✅ **Includes historical AND current data** — so you can track trends, not just snapshots ✅ **Custom-built to your needs** — you tell us your focus (condition, phase, region, sponsor type) and we personalize the dashboard to fit you.

---

Call Before Purchase – Here’s Why

Because this isn’t a one-size-fits-all product. Every investor, startup, or pharma exec has a unique focus — oncology vs rare disease, early-stage vs late-stage trials, US vs global markets.

That’s why you must call me directly before purchase, so I can personally customize your dashboard to fit your strategy.

Contact Rohan Duhaney
Phone: (856) 522-3601
Email: [email protected]

---

Future Price Increases

The current price of **$1500.00 USD** reflects the early release version. As new data sources, advanced modeling, and predictive AI get added, the price will increase significantly.

**Secure your personalized dashboard now at today’s rate — and lock in free updates for the first 60 days.**

---

Ready to See What Real Clinical Intelligence Feels Like?

Call me today — and let’s build your **custom intelligence engine** so you can make smarter, faster decisions in clinical development and biotech investing.

Rohan Duhaney

Phone: 856-522-3601
Email: [email protected]
Website: smartduhaney.com

 

PROOF OF WORK

 


        Healthcare Solutions Dashboard Output
        Brought to you by Rohan Duhaney
        Contact: 856-522-3601 | Email: [email protected] | Website: smartduhaney.com
        ----------------------------------------------------------------------
        Condition: Sickle Cell Disease
        Cure: DRUG: ATG|DRUG: fludarabine|DRUG: cyclophosphamide|RADIATION: Total body irradiation|PROCEDURE: Stem cell infusion|DRUG: Sirolimus|DRUG: mycophenolate mofetil

        For Investors only investing in a study:
        Financial Forecast:
        • Total Cost per Patient: $250,000.00
        • Total Revenue per Patient: $2,100,000.00
        • ROI: 740.0%

        NCT Number: NCT03121001
        Study Phase: PHASE2
        Study Status: RECRUITING

        Additional Insights:
        • Devices/Interventions: No device listed
        • Enrollment: 50
        • Sponsor: University of Illinois at Chicago
        ----------------------------------------------------------------------
        

        Healthcare Solutions Dashboard Output
        Brought to you by Rohan Duhaney
        Contact: 856-522-3601 | Email: [email protected] | Website: smartduhaney.com
        ----------------------------------------------------------------------
        Condition: HbS Disease|Hemoglobin S Disease|Sickle Cell Anemia|Sickle Cell Disorders|Sickling Disorder Due to Hemoglobin S|Sickle Cell Disease
        Cure: OTHER: TCRα/β+ and CD19+ depleted haploidentical stem cell transplantation|OTHER: Matched sibling donor transplantation

        For Investors only investing in a study:
        Financial Forecast:
        • Total Cost per Patient: $1,060,000.00
        • Total Revenue per Patient: $8,904,000.00
        • ROI: 740.0%

        NCT Number: NCT04201210
        Study Phase: PHASE2
        Study Status: RECRUITING

        Additional Insights:
        • Devices/Interventions: No device listed
        • Enrollment: 212
        • Sponsor: University of Regensburg
        ----------------------------------------------------------------------
        

        Healthcare Solutions Dashboard Output
        Brought to you by Rohan Duhaney
        Contact: 856-522-3601 | Email: [email protected] | Website: smartduhaney.com
        ----------------------------------------------------------------------
        Condition: Sickle Cell Disease|Diffuse Myocardial Fibrosis
        Cure: DRUG: Losartan

        For Investors only investing in a study:
        Financial Forecast:
        • Total Cost per Patient: $120,000.00
        • Total Revenue per Patient: $1,008,000.00
        • ROI: 740.0%

        NCT Number: NCT05012631
        Study Phase: PHASE2
        Study Status: RECRUITING

        Additional Insights:
        • Devices/Interventions: No device listed
        • Enrollment: 24
        • Sponsor: Children's Hospital Medical Center, Cincinnati
        ----------------------------------------------------------------------
        We HAVE UNLIMITED INFORMATION READY TO EXPLORE

Shipping Notes
  • Free Standard Shipping on $100+ Orders to the USA.
  • Except Preorder products are shipped in 48 hours.
  • Delivery to the USA:
  1. Standard Shipping : 3-10 business days
  • If time is of the essence, please consider selecting expedited delivery for faster service.
Exchange/Return Notes
  • We offer a 30-day return/exchange service after receiving.
  • Final sale items are not eligible for returns or exchanges.
  • To process your return/exchange, please contact us at [email protected]
  • Please click here for more details>>> Return & Exchange Policy
SKU: 88867085907

Discover Niche Categories That Outsell

Top-Converting Item to Boost Your Average Order

4.2 ★★★★★
Based on 537 reviews
Sort
Highest Rating
Newest First
Oldest First
Product Reviews
E
Verified Purchase
❈ Elizabeth ❈ | Breakawayreads
Alexandria, US
★★★★★ 5
Fallen Angels, fae, vampires, oh my!
Format: Kindle
Rating: 4.5 | Spice: 2 (but a good slow-burn) • Main Characters: Huntyr and Wolf • I couldn’t wait to read this book; there was so much hype about it! And there was no doubt why. I fell in love with the characters and the plot itself. This book is mainly plot driven more than friction driven but it’s easy to follow along with. The characters are fun, easily understood. The main setting is at an academy where both the main characters are going through trials and building strength for the final test, The Transcendent. There are fantastic side characters as well. I loved the camaraderie between Huntyr and her friends. But we don’t like Lanson. 😆 We do have some plot twists that come into play throughout the book. Secrets and betrayal to be seen. I did adore Wolf and Huntyr’s relationship. It was a classic slow burn trope. They didn’t hit it off fast, but in time their feelings grew. I loved their banter, so sexy. Wolf is your next book boyfriend; Huntyr is your next vampire assassin independent bad-a*s female. Themes include loyalty, trust, self-discovery, a true slow burn romance. Side note: book ends on a angsty cliffhanger! • Emily, thank you for writing this awesome novel and I cannot wait to devour Book 2, Blood So Brutal! 😍 • Happy reading, my lovelies! xo
WAS THIS REVIEW HELPFUL?YesReportShare
Reviewed in the United States on January 21, 2024
M
Verified Purchase
MelsABookworm
San Leandro, US
★★★★★ 4
“My heart bows to you and you only, Huntress.”
Format: Kindle
3.5 🌟 This book popped up in my KU recommended reading suggestions and the synopsis sounded like what I was in the mood for. I'm so glad I took a chance on it. I went into this knowing absolutely nothing about it and ended up really liking it. I love when this happens. The main characters are likeable and I easily found myself rooting for them. There is a mystery element to each of their backstories that I enjoyed watching unfold and can't wait to get more of. Wolf, in particular, has me fixated. Love him. I found this to be an entertaining, addictive read with a plot that moves along at a good pace. It reads so easily I found myself very reluctant to put it down. Lots of twists and turns and the angst is there. A good set up for the next book to come, for sure. My issues with this book....the dialogue feels a bit juvenile at times and there is a repetitive over use of a particular word phrasing that I found myself giving the ole eye-roll to. There are, without a doubt, some pretty cliche moments that gave me a bit of the cringe. I think this could've certainly 100% benefited from more depth regarding the world building. Perhaps the world building was sacrificed to keep the pacing quick? Just a guess. Also, the lack of consistency of character for the FMC was really evident and so she feels quite illogical at times. Overall, this was a fun and enjoyable read that hit the spot well enough for me. That ending certainly has me impatiently pining for book 2!
WAS THIS REVIEW HELPFUL?YesReportShare
Reviewed in the United States on June 18, 2024
A
Verified Purchase
Amazon Customer
Houston, US
★★★★★ 3
Interesting take on the genre
Format: Kindle
True rating: 3.25 ⭐️ I enjoyed the fresh take on the genre. The best way I could describe the setting and world is an apocalyptic dystopian version of Farie where vampires, fae, and angles struggle to survive in what is left of the world. It was definitely interesting throwing the academy/hunger games aspect into this world as well. Even though I guessed the final reveal early on in the book, I kept hoping I was wrong, and it would take a surprising turn. While the "plot twists" were a bit predictable to me, I still enjoyed the ride this book took me on. Another downfall for me was the plot holes in the world building... I.E. if society has fallen and the world is in the aftermath of war, how are there trains running around the world? Just to take young adults to the trials to get into the golden city? How is the train maintained, the tracks clear, etc? However, I did enjoy the FMC & MMC and thought they were fleshed out nicely. I also enjoyed the side characters but wish some were developed more like Ashalin (sp?). I do find myself rooting for the MCs to succeed and find happiness together, which is obviously an important aspect for romantasy. Overall, was this an earth-shattering, mind-bending, terrific piece of literature? No. But was it the worst thing I've read this year? Also, no. This book has, to me, the bones of a great read & just needs a bit more to push it from an alright book to a great book. Overall ratings: Plot- 3.5⭐️ World building 3⭐️ Spice 2.5 🌶🌶 Main characters 4 ⭐️ Supporting characters 3.5⭐️
WAS THIS REVIEW HELPFUL?YesReportShare
Reviewed in the United States on May 12, 2024
I
Verified Purchase
Irene zamora
Fort Morgan, US
★★★★★ 5
great book
Format: Kindle
I am really excited to meet the author at the book retreat this month. I really enjoyed this world that she built and most of the female main character Huntress is so awesome. She goes through a lot in this book and the ending; wow! I wouldn't have even guessed. I highly recommend everyone to read this book. I have been so lucky this year that almost all the books I have read have been, so far, 5 out 5 stars.
WAS THIS REVIEW HELPFUL?YesReportShare
Reviewed in the United States on June 2, 2026
A
Verified Purchase
Anastasia Goygova
Omaha, US
★★★★★ 4
Fallen for the Fallen Angel – A Guilty Pleasure Worth Every Page
Format: Kindle
There’s something deeply irresistible about a dark academia or trial-based setting, a brooding and arrogant fallen angel, and a fierce heroine with enough sass to go toe-to-toe with him. Wings So Wicked is exactly that kind of book—and I devoured it in just a couple of days. To be fair, the plot isn’t groundbreaking. If you’re looking for something fresh and innovative in terms of storyline, this might not be it. But if your reader heart beats faster at the mere mention of enemies-to-lovers, jealousy-fueled banter, magical trials, betrayals, and forbidden tension—you’ll feel right at home. It’s like catnip for those of us with this particular weakness. The chemistry between the leads could have used a slightly slower burn to make the tension sizzle longer, but I still found myself completely invested in their dynamic. There are moments and phrases that feel a bit cheesy or underdeveloped, but honestly? I didn’t care. The vibes were exactly what I wanted. This book isn’t trying to reinvent the genre—it’s here to give readers like me what we crave: high-stakes magical drama, angsty romance, and the thrill of watching a badass girl and her brooding counterpart clash and spark. If that sounds like your kind of story, Wings So Wicked will hit the mark. Here’s hoping Book 2 turns up the heat and keeps the magic alive.
WAS THIS REVIEW HELPFUL?YesReportShare
Reviewed in the United States on May 20, 2025

recommand products